Ratings by Barrington Research (Michael Petusky)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/29/2026 | Opko Health | OPK | Downgrade | Market Perform (Outperform) |
1.21 (1.50) |
23.97% | Details | |
| 3/17/2026 | Lifecore Biomedical | LFCR | Upgrade | Outperform (Market Perform) |
4.37 (5.60) |
28.15% | Details | |
| 2/9/2026 | Bioventus Inc | BVS | New Coverage | Outperform (N/A) |
8.51 (9.60) |
12.81% | Details | |
| 11/14/2025 | SurModics | SRDX | Downgrade | Underperform (Market Perform) |
41.41 (42.98) |
3.79% | Details | |
| 5/27/2025 | ModivCare | MODV | Maintain | Market Perform (Outperform) |
|
Details | ||
| 5/12/2025 | ModivCare | MODV | Downgrade | Market Perform (Outperform) |
1.17 (0.43) |
-63.25% | Details | |
| 3/7/2025 | VerifyMe | VRME | Maintain | Outperform (N/A) |
|
Details | ||
| 3/7/2025 | ModivCare | MODV | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2024 | DENTSPLY SIRONA | XRAY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/30/2024 | SurModics | SRDX | Downgrade | Market Perform (Outperform) |
42.10 (41.41) |
-1.64% | Details | |
| 5/2/2024 | SurModics | SRDX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2023 | Anika Therapeutics | ANIK | Upgrade | Outperform (Market Perform) |
18.38 (14.81) |
-19.42% | Details | |
| 6/29/2023 | Opko Health | OPK | Upgrade | Outperform (Market Perform) |
1.72 (1.21) |
-29.65% | Details | |
| 5/10/2023 | Henry Schein | HSIC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/7/2023 | Anika Therapeutics | ANIK | Downgrade | Market Perform (Outperform) |
28.87 (14.81) |
-48.7% | Details | |
| 2/8/2023 | Haemonetics | HAE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2023 | SurModics | SRDX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/20/2023 | SurModics | SRDX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2022 | Anika Therapeutics | ANIK | Upgrade | Outperform (Market Perform) |
27.37 (14.81) |
-45.89% | Details | |
| 8/11/2022 | Haemonetics | HAE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2022 | Landec | LNDC | Upgrade | Outperform (Market Perform) |
11.02 (8.76) |
-20.51% | Details | |
| 8/3/2022 | Henry Schein | HSIC | Maintain | Outperform (N/A) |
|
Details | ||
| 4/6/2022 | Landec | LNDC | Downgrade | Market Perform (Outperform) |
11.33 (8.76) |
-22.68% | Details | |
| 4/5/2022 | Tivity Health | TVTY | Downgrade | Market Perform (Outperform) |
32.25 (32.50) |
0.78% | Details | |
| 3/9/2022 | Anika Therapeutics | ANIK | Downgrade | Market Perform (Outperform) |
30.60 (14.81) |
-51.6% | Details | |
| 2/25/2022 | Tivity Health | TVTY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2021 | Haemonetics | HAE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2021 | Tivity Health | TVTY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/30/2021 | Landec | LNDC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2021 | DENTSPLY SIRONA | XRAY | Upgrade | Outperform (Market Perform) |
59.71 (10.78) |
-81.95% | Details | |
| 2/3/2021 | Haemonetics | HAE | Upgrade | Outperform (Market Perform) |
129.93 (75.41) |
-41.96% | Details | |
| 1/21/2021 | Haemonetics | HAE | Downgrade | Market Perform (Outperform) |
124.57 (75.41) |
-39.46% | Details | |
| 12/16/2020 | Anika Therapeutics | ANIK | Upgrade | Outperform (Market Perform) |
38.45 (30.60) |
-20.42% | Details | |
| 11/5/2020 | Haemonetics | HAE | Upgrade | Outperform (Market Perform) |
102.20 (75.41) |
-26.21% | Details | |
| 11/3/2020 | Henry Schein | HSIC | Upgrade | Outperform (Market Perform) |
63.58 (84.04) |
32.18% | Details | |
| 5/26/2020 | Providence Service | PRSC | New Coverage | Outperform (N/A) |
75.49 (155.58) |
106.09% | Details | |
| 5/11/2020 | DENTSPLY International | XRAY | Downgrade | Market Perform (Outperform) |
40.65 (10.78) |
-73.48% | Details | |
| 5/8/2020 | Anika Therapeutics | ANIk | Downgrade | Market Perform (Outperform) |
34.55 (14.81) |
-57.13% | Details | |
| 5/7/2020 | Tivity Health | TVTY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2020 | Henry Schein | HSIC | Downgrade | Market Perform (Outperform) |
53.70 (84.04) |
56.5% | Details | |
| 5/6/2020 | Haemonetics | HAE | Downgrade | Market Perform (Outperform) |
106.38 (75.41) |
-29.11% | Details | |
| 4/24/2020 | Merit Medical Systems, Inc. | MMSI | Upgrade | Outperform (Market Perform) |
37.86 (70.82) |
87.06% | Details | |
| 2/25/2020 | Merit Medical Systems, Inc. | MMSI | Downgrade | Market Perform (Outperform) |
38.75 (70.82) |
82.76% | Details | |
| 1/6/2020 | Landec | LNDC | Downgrade | Market Perform (Outperform) |
10.03 (8.69) |
-13.36% | Details | |
| 11/4/2019 | Haemonetics | HAE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2019 | Henry Schein | HSIC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2019 | Haemonetics | HAE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2019 | DENTSPLY International | XRAY | Upgrade | Outperform (Market Perform) |
55.05 (40.65) |
-26.16% | Details | |
| 5/2/2019 | LeMaitre Vascular | LMAT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2018 | Henry Schein | HSIC | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2018 | BioScrip | BIOS | Maintain | Outperform (N/A) |
|
Details |
